Stroke remains one of the main causes of death and disability worldwide. The challenge of
predicting stroke outcome has been traditionally assessed from a general point of view …

Stroke is the third leading cause of death in industrialized countries and one of the largest
causes of permanent disability worldwide. Therapeutic options to fight stroke are still limited …

NR4A2 is a nuclear receptor and a transcription factor, with distinctive physiological
features. In the cell nuclei of the central nervous system, it is widely expressed and identified …

Ischemic stroke is a major disability and cause of death worldwide due to its narrow
therapeutic time window. Neuroprotective agent is a promising strategy to salvage acutely …

Tissue plasminogen activator (t-PA) is the only FDA-approved drug for acute ischemic stroke
treatment, but its clinical use is limited due to the narrow therapeutic time window and …

Reperfusion therapy contributes to better clinical outcomes in patients with acute ischemic
stroke but carries a more significant risk of hemorrhagic transformation (HT) compared to …

Ischemic stroke is amongst the leading causes of death and disabilities. The available
treatments are suitable for only a fraction of patients and thus novel therapies are urgently …

Previously, we only apply a traditional Chinese medicine (TCM) Danshen-Chuanxiong-
Honghua (DCH) for cardioprotection via anti-inflammation in rats of acute myocardial …

Nurr1 is a member of the orphan nuclear receptor family NR4A (nuclear receptor subfamily 4
group A) that modulates inflammation in several cell lineages, both positively and …

The risk of intracerebral hemorrhage still greatly limits the use of tPA in stroke patients.
Research is ongoing in order to identify the pathophysiological mechanisms at play, detect …